传奇生物 LEGN
$23.40 +$0.86 (+3.82%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $23.47 +0.30%
开盘$23.09
昨收$22.54
当日区间$22.57 – $23.74
成交量1.77M
市值$4.55B
市盈率（TTM）–
股息率–
LEGN 相关新闻
匹配 Legend Biotech 或代码 LEGN 的头条新闻，按最新排序。
- H.C. Wainwright Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $65
- RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $58
- Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $74 负面
- UBS Maintains Legend Biotech(LEGN.US) With Hold Rating, Maintains Target Price $28
- A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $24 to $48
- A Quick Look at Today's Ratings for Legend Biotech(LEGN.US), With a Forecast Between $24 to $65
- Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT)
- Analysts Have Conflicting Sentiments on These Healthcare Companies: Intuitive Surgical (ISRG), Legend Biotech (LEGN) and Mineralys Therapeutics, Inc. (MLYS)
- RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $63 负面
- RBC Capital Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $59 负面
- UBS Downgrades Legend Biotech(LEGN.US) to Hold Rating, Cuts Target Price to $28 负面
- Goldman Sachs Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $40.5 负面
- Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $80
- J.P. Morgan Downgrades Legend Biotech(LEGN.US) to Hold Rating, Cuts Target Price to $35 负面
- UBS Maintains Legend Biotech(LEGN.US) With Buy Rating, Maintains Target Price $49
暂无评论——快来第一个聊聊 LEGN。
登录后参与讨论。